Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests

Oncotarget. 2016 Jul 19;7(29):45122-45133. doi: 10.18632/oncotarget.9161.

Abstract

The increase in cellular radiosensitivity by EGF receptor (EGFR) inhibition has been shown to be attributable to the induction of a G1-arrest in p53-proficient cells. Because EGFR targeting in combination with radiotherapy is used to treat head and neck squamous cell carcinomas (HNSCC) which are predominantly p53 mutated, we tested the effects of EGFR targeting on cellular radiosensitivity, proliferation, apoptosis, DNA repair and cell cycle control using a large panel of HNSCC cell lines. In these experiments EGFR targeting inhibited signal transduction, blocked proliferation and induced radiosensitization but only in some cell lines and only under normal (pre-plating) conditions. This sensitization was not associated with impaired DNA repair (53BP1 foci) or induction of apoptosis. However, it was associated with the induction of a lasting G2-arrest. Both, the radiosensitization and the G2-arrest were abrogated if the cells were re-stimulated (delayed plating) with actually no radiosensitization being detectable in any of the 14 tested cell lines. Therefore we conclude that EGFR targeting can induce a reversible G2 arrest in p53 deficient HNSCC cells, which does not consequently result in a robust cellular radiosensitization. Together with recent animal and clinical studies our data indicate that EGFR inhibition is no effective strategy to increase the radiosensitivity of HNSCC cells.

Keywords: EGFR; HNSCC; cell cycle; radiosensitization; targeting.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Carcinoma, Squamous Cell / genetics
  • Carcinoma, Squamous Cell / pathology*
  • Cell Cycle Checkpoints / drug effects
  • Cell Line, Tumor
  • Cetuximab / pharmacology
  • ErbB Receptors / antagonists & inhibitors*
  • Erlotinib Hydrochloride / pharmacology
  • Head and Neck Neoplasms / genetics
  • Head and Neck Neoplasms / pathology*
  • Humans
  • Radiation Tolerance / drug effects*
  • Squamous Cell Carcinoma of Head and Neck
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Antineoplastic Agents
  • Tumor Suppressor Protein p53
  • Erlotinib Hydrochloride
  • EGFR protein, human
  • ErbB Receptors
  • Cetuximab